PTPRC and neoplasm: Because IRAK3 is predominantly expressed by myeloid cells, we found strong correlations between IRAK3 and immune cell markers including CD45, CD11b, and CD11c in pretherapy tumor samples (Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI161084DS1).